Osaic Holdings Inc. Boosts Stake in Medpace Holdings, Inc. $MEDP

Osaic Holdings Inc. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 55.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 6,334 shares of the company’s stock after buying an additional 2,258 shares during the quarter. Osaic Holdings Inc.’s holdings in Medpace were worth $1,988,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Employees Retirement System of Texas purchased a new stake in Medpace in the 2nd quarter valued at $36,000. IFP Advisors Inc boosted its stake in Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after purchasing an additional 134 shares during the period. Hantz Financial Services Inc. boosted its stake in Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after purchasing an additional 203 shares during the period. Finally, Cary Street Partners Investment Advisory LLC grew its position in Medpace by 514.3% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after purchasing an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.8%

Shares of MEDP opened at $567.56 on Monday. The stock’s 50 day moving average is $579.62 and its two-hundred day moving average is $482.65. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The firm has a market capitalization of $15.99 billion, a PE ratio of 39.69, a P/E/G ratio of 2.14 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period last year, the firm earned $3.01 EPS. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 387,925 shares of company stock valued at $233,386,647. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on MEDP. Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Mizuho increased their price objective on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Finally, Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and upped their price target for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $490.82.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.